Bristol Myers Squibb (BMY) Wins FDA Filing And Nvidia Tie Up, Is It Still Undervalued?

Bristol-Myers Squibb (BMY) is back in focus after the FDA accepted its New Drug Application for mezigdomide in relapsed or refractory multiple myeloma, alongside a new AI collaboration with Nvidia for drug discovery.

See our latest analysis for Bristol-Myers Squibb.

The recent FDA filing for mezigdomide and the AI expansion with Nvidia come as Bristol-Myers Squibb’s share price has gained momentum, with a 12.83% 1 month share price return and 13.97% year to date, while the 1 year total shareholder return sits at 32.97%.

If you are interested in how AI is reshaping healthcare beyond Bristol-Myers Squibb, this could be a good moment to scan the wider field through our 39 healthcare AI stocks

Bulls see Bristol-Myers Squibb’s mezigdomide data and Nvidia-backed AI push as proof the recent share price momentum has a solid footing, while bears point to falling revenue and earnings. Which story does the current valuation support?

Most Popular Narrative: 3.2% Undervalued

The most followed narrative currently places Bristol-Myers Squibb’s fair value at $62.96 versus a last close of $60.93, setting up a tight valuation debate around what the pipeline and margins need to deliver.

Robust late-stage pipeline and ongoing life-cycle management for major brands, plus partnerships expand the breadth of future regulatory approvals and label expansions, opening additional indications and helping to offset upcoming patent expiries, which underpins top-line and earnings growth.

Read the complete narrative.

Want to see what sits behind that confidence in Bristol-Myers Squibb’s pipeline and margins? The narrative leans on shifting revenue mix, higher profits, and a richer future earnings multiple.

Result: Fair Value of $62.96 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, this Bristol-Myers Squibb narrative can be tested quickly if patent cliffs on key drugs bite harder than expected or if new launches and trials disappoint.

Find out about the key risks to this Bristol-Myers Squibb narrative.

Next Steps

With Bristol-Myers Squibb carrying both clear risks and clear rewards, this is a good time to move quickly, review the data, and weigh the 3 key rewards and 3 important warning signs.

Looking for more investment ideas beyond Bristol-Myers Squibb?

If Bristol-Myers Squibb has you thinking more broadly about opportunities, now is a smart time to widen your search and compare different types of stocks efficiently.

• Target steady compounding potential by reviewing companies that appear mispriced on quality and fundamentals with the 50 high quality undervalued stocks.
• Prioritise resilience in tough markets by scanning companies that score well on financial strength through the 81 resilient stocks with low risk scores.
• Spot future contenders early by checking the screener containing 20 high quality undiscovered gems before they move onto everyone else's radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com